A kind of cyp17 inhibitor soft capsule and preparation method thereof

A technology of capsules and fatty acid glycerides, which is applied in the field of CYP17 inhibitor soft capsules and its preparation, can solve the problems of complex preparation process, lower drug stability, slow drug dissolution, etc., and achieve simple preparation process, increase dissolution rate and bioavailability degree, to avoid the effect of stimulation

Active Publication Date: 2020-07-31
LUNAN PHARMA GROUP CORPORATION
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The prescription ingredients and preparation process are relatively complicated, and the preparation process requires further heating, which reduces the stability of the drug, affects the safety of the drug, and cannot solve the problem of drug bioavailability
[0012] At present, in the oral preparations of abiraterone acetate, there are shortcomings such as slow drug dissolution and low bioavailability. In the liquid capsule preparation process, the process is complicated, and industrial production is difficult, and the dissolution rate and bioavailability of the prepared abiraterone acetate solid preparation degree to be further improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of cyp17 inhibitor soft capsule and preparation method thereof
  • A kind of cyp17 inhibitor soft capsule and preparation method thereof
  • A kind of cyp17 inhibitor soft capsule and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] 1) Prescription

[0028] Component content g

[0029] Abiraterone Acetate 10

[0030] Glyceryl monooleate 40

[0031] 2) Preparation process:

[0032] Prescription quantity takes abiraterone acetate and glycerol monooleate, stirs to dissolve and become a uniform clear solution, and fills the solution into soft capsules.

Embodiment 2

[0034] 1) Prescription

[0035] Component content g

[0036] Abiraterone Acetate 10

[0037] Polyoxyethylene Glyceryl Oleate 100

[0038] 2) Preparation process:

[0039] Prescription amount weighs abiraterone acetate and polyoxyethylene olein glyceride, stirs to dissolve into a uniform clear solution, and fills the solution into soft capsules.

Embodiment 3

[0041] 1) Prescription

[0042] Component content g

[0043] Abiraterone Acetate 10

[0044] Macrogol Glyceride Oleate 150

[0045] 2) Preparation process:

[0046] Prescription amount weighs abiraterone acetate and macrogol glyceride oleate, stirs to dissolve and become a uniform clear solution, and fills the solution into soft capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of western medicine preparation, and specifically provides a CYP17 inhibitor soft capsule. The abiraterone acetate is dissolved in fatty glyceride to makea uniform clear solution, and the soft capsule is filled with the solution. The use of fatty glyceride in the soft capsule can stimulate the contraction of bile vesicles, increases the concentration of bile salts, phospholipids and cholesterol in the small intestine, and improves the dissolution and solubility in the body, prolongs the gastrointestinal retention time, stimulates lymphatic transport, reduces metabolic effects, and further increases the bioavailability of abiraterone acetate.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a CYP17 inhibitor soft capsule and a preparation method thereof. Background technique [0002] Abiraterone acetate is an oral CYP17 inhibitor, which reduces androgen levels by inhibiting the key enzyme in androgen synthesis - CYP450c17, and has inhibitory effects on androgens in the testis and other parts of the body. It is used for the treatment of advanced prostate cancer. Its structural formula is: [0003] [0004] Abiraterone acetate is a lipophilic compound, easily soluble in organic solvents such as tetrahydrofuran, dichloromethane, especially alcohols; almost insoluble in water at pH2-12 at 20°C; slightly soluble in 0.1N hydrochloric acid, BCS classification belongs to Four types, so improving its dissolution rate and bioavailability is the key of the present invention when carrying out pharmaceutical preparation research. [0005] Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/48A61K31/58A61K47/14A61P5/28A61P35/00
CPCA61K9/4858A61K31/58A61P5/28A61P35/00
Inventor 张贵民郝贵周王苗苗
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap